

Additional file 2

Data extraction form adapted from Hayden et al Framework

Abbreviation

IGT	Impaired Glucose Tolerance
CKD	Chronic Kidney Disease
T2DM	Type 2 Diabetes
SCr	Serum Creatinine
CrCl	Creatinine Clearance
ESRD	End Stage Renal Disease
ACR	Albumin Creatinine Ratio
PCR	Protein Creatinine Ratio
EX	Excluded
NR	Not Reported
eGFR	Estimated Glomerular Filtration Rate

Eligibility criteria for title and abstract screening phase

Study design	Assessment	Comment
Is it: [1] A cohort study (Prospective or Retrospective) [2] A case-control or nested case-control study	Yes No Unclear	
Population		
[1] Were patients diagnosed with IGT? [2] Were patients followed up for T2DM NB: Please answer Yes if IGT diagnosed in a sub group	Yes No Unclear	
Are patients aged (18-40) years NB: Please answer Yes if mixed age population	Yes No Unclear	

Study design	Assessment	Comment										
Outcomes												
<p>Did the study report any of the following outcome:</p> <table border="1" data-bbox="152 304 533 576"> <thead> <tr> <th>Stage</th> <th>eGFR (ml/min/1.73m²)</th> </tr> </thead> <tbody> <tr> <td>3A</td> <td>45-59</td> </tr> <tr> <td>3B</td> <td>30-44</td> </tr> <tr> <td>4</td> <td>15-29</td> </tr> <tr> <td>5</td> <td><15</td> </tr> </tbody> </table> <p>ESRD (stage 5) Albuminuria ACR - >30mg/mmol PCR - >45mg/mmol SCr measures CrCl measures</p>	Stage	eGFR (ml/min/1.73m ²)	3A	45-59	3B	30-44	4	15-29	5	<15	Yes No Unclear	
Stage	eGFR (ml/min/1.73m ²)											
3A	45-59											
3B	30-44											
4	15-29											
5	<15											
Follow up												
<p>Were the patients followed up and adequate measures taken</p> <p>NB: Please answer Yes if adequate measure were taken and key characteristics described</p>	Yes No Unclear											
Final decision (please tick)	Include Exclude Unclear											

Exclusion criteria

Reasons for exclusion of study from review (please circle where appropriate)	
Methods	Not a cohort/case-control study
Patients	No IGT/no T2DM follow up/T2DM or Type 1 diabetes diagnosis /CKD /no (18 to 40 years) age group
Outcomes	No relevant outcomes assessed No data for relevant subgroup extractable
Follow up period	No follow up
Other	Duplicate publication Other

Inclusion criteria

Specific inclusion criteria (please include if answer is Yes to all questions below)	
Eligibility criteria	
Satisfaction of eligibility criteria	Yes No Unclear
Effect sizes	
Is there sufficient reporting of statistics or data to calculate effect sizes	Yes No Unclear

Organisation

Organisational aspect		Exclude		Include
Reviewer/date:		Checked by:		
Author/Year				
Journal/Source				
Country of origin				
Publication type	Full text/Abstract/Book chapter/progress report/ Other – please specify			
Fate	Decision pending/Check references/Use for discussion/EX without listing/EX with listing Other – please specify			
Notes				

Study characteristics

General study characteristics (please circle where appropriate)											
Location of study											
Study aims	Reported/NR										
Dates of recruitment	From _____ to _____ Median (range): # Mean:#										
Length of follow up of CKD outcome + length of follow up of study	From _____ to _____ Median (range): # Mean:#										
Outcomes assessed	<p>Did the study report any of the following outcome:</p> <table border="1"> <thead> <tr> <th>Stage</th> <th>eGFR (ml/min/1.73m²)</th> </tr> </thead> <tbody> <tr> <td>3A</td> <td>45-59</td> </tr> <tr> <td>3B</td> <td>30-44</td> </tr> <tr> <td>4</td> <td>15-29</td> </tr> <tr> <td>5</td> <td><15</td> </tr> </tbody> </table> <p>End Stage Renal Disease (stage 5) Albumin creatinine ratio - >30mg/mmol Protein creatinine ratio - >45mg/mmol Serum creatinine measures Creatinine clearance measures Other (<i>please specify</i>):</p>	Stage	eGFR (ml/min/1.73m ²)	3A	45-59	3B	30-44	4	15-29	5	<15
Stage	eGFR (ml/min/1.73m ²)										
3A	45-59										
3B	30-44										
4	15-29										
5	<15										
Outcome definition											
Relationship between outcome and relevant factor	<p>Is the relationship statistically significant? Yes/No RR/OR: #</p> <p>If No, is it due to Low powered or inconclusive study/A true negative study</p>										
Power calculation	<p>Yes/No/Not reported</p> <p>Calculated sample size: # Sample size achieved: Yes/No</p>										
Funding	<p>Unclear NR Please state where reported</p>										
Conflict of interest statement	Yes/No/NR										

Baseline characteristics of patients (please circle where appropriate)

	Exposure	Control	Notes: any relationship with outcomes? Yes/No/NR If Yes please state if statistically significant and RR/OR values						
Overall comment: Significant/In significant									
Number of patients									
Age range (if reported) Mean									
Ethnicity No%									
Gender No%	Male: Female:	Male: Female:							
No of patients screened for IGT									
No of patients recruited									
No of patients allocated									
No of patients evaluated									
No of dropouts									
Reasons for dropouts									
Number of protocol violations									
Definition of IGT									
<table border="1"> <tr> <td>Fasting plasma glucose</td> <td>6.1-6.9 mmol/L</td> </tr> <tr> <td>Oral Glucose Tolerance test (2h value)</td> <td>7.8-11.0 mmol/L</td> </tr> <tr> <td>HbA1c</td> <td>42-47 mmol/mol</td> </tr> </table>	Fasting plasma glucose	6.1-6.9 mmol/L	Oral Glucose Tolerance test (2h value)	7.8-11.0 mmol/L	HbA1c	42-47 mmol/mol			
Fasting plasma glucose	6.1-6.9 mmol/L								
Oral Glucose Tolerance test (2h value)	7.8-11.0 mmol/L								
HbA1c	42-47 mmol/mol								
Please circle all that applies and list all									
Status of patient at recruitment									
Any treatment for any comorbidities									
If treated: Please state									
What treatment									
Duration									
Adverse event? Yes/No									
<i>If Yes please state</i>									

Observational study characteristics (please circle where appropriate)	
Sample size	
Number of excluded patients	
Recruitment method	
Type of observational study	Cohort studies (retrospective/prospective) Case-control studies/nested case-control
Are group comparable?	Yes/No If No, please specify
Any confounders?	Yes/No If No, please specify
Analysis	
Drop outs stated	Yes/No If Yes: # in each group

Outcome details

The following table have to be copied for every relevant outcome assessed (*please fill out fields only where applicable*)

Outcomes assessed (please state where relevant)	
Definition of each outcome	
Time of assessment of each outcome (post IGT)	
Timing of assessment	
Length of follow up for each outcome	
Method of measurement	
No of patients evaluated for each outcome, as stated above	

Methodological quality summary for observational studies

Reviewer/Date:		Checked by:			
Contents (please refer to tables below for guidance)	Yes	Partly	No	Unsure	Comments
Study participation					
Study attrition					
Measurement of prognostic factors					
Measurement and controlling for confounding variables					
Measurement of outcomes					
Analysis approach					
Summarised validity	Low risk of bias		Moderate risk of bias		High risk of bias
Remarks:					